Time to target uric acid to retard CKD progression (Q38848997)

7 September 2017

1 reference

title

Time to target uric acid to retard CKD progression (English)

1 reference

7 September 2017

Takanori Kumagai

1

1 reference

7 September 2017

Tatsuru Ota

2

1 reference

7 September 2017

Yoshifuru Tamura

3

1 reference

7 September 2017

Wen Xiu Chang

4

1 reference

7 September 2017

Shigeru Shibata

5

1 reference

7 September 2017

Shunya Uchida

6

1 reference

7 September 2017

23 June 2016

1 reference

Clinical and experimental nephrology

7 September 2017

1 reference

7 September 2017

21

1 reference

7 September 2017

182-192

1 reference

7 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s10157-016-1288-2

7 September 2017

0 references

cites work

Chronic kidney disease: global dimension and perspectives

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Association of kidney disease outcomes with risk factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid and chronic kidney disease: which is chasing which?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Two independent mutational events in the loss of urate oxidase during hominoid evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Molecular physiology of urate transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Urate oxidase: primary structure and evolutionary implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Towards the physiological function of uric acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

The crystallization of monosodium urate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Renal transport of uric acid: evolving concepts and uncertainties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Postsecretory reabsorption of urate in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Genome-wide association study of hematological and biochemical traits in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Urate transporters in the genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Decreased extra-renal urate excretion is a common cause of hyperuricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

The effect of testosterone upon the urate reabsorptive transport system in mouse kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

The effect of female hormones upon urate transport systems in the mouse kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Hyperuricemia and gout. Classification, complications and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid metabolism of kidney and intestine in a rat model of chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Mild hyperuricemia induces glomerular hypertension in normal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

A role for uric acid in the progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Hyperuricemia causes glomerular hypertrophy in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid as a mediator of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric Acid is independently associated with diabetic kidney disease: a cross-sectional study in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Relationship of uric acid with progression of kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Elevated uric acid increases the risk for kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Risk factors for end-stage renal disease: 25-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Association of uric acid with change in kidney function in healthy normotensive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid levels predict future development of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Hyperuricemia is associated with progression of IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Association of a polymorphism in a gene encoding a urate transporter with CKD progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid and incident kidney disease in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid and long-term outcomes in CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Serum uric acid and the incidence of CKD and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Predictors and the Subsequent Risk of End-Stage Renal Disease - Usefulness of 30% Decline in Estimated GFR over 2 Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Time-dependent risk factors associated with the decline of estimated GFR in CKD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Targeting Uric Acid and the Inhibition of Progression to End-Stage Renal Disease--A Propensity Score Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid transport in renal failure. A review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Mendelian randomization: genetic anchors for causal inference in epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric Acid and Cardiovascular Events: A Mendelian Randomization Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

SLC2A9--a fructose transporter identified as a novel uric acid transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Elevated serum uric acid predicts chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Serum uric acid level, longitudinal blood pressure, renal function, and long-term mortality in treated hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid as a cardiometabolic risk factor: to be or not to be.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Allopurinol for prevention of progression of kidney disease with hyperuricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid and chronic kidney disease: new understanding of an old problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-016-1288-2

Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients

21 January 2018

1 reference

12 December 2020

Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease

1 reference

12 December 2020

Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction

1 reference

12 December 2020

Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes

1 reference

12 December 2020

Renal handling of uric acid in normal subjects by means of the pyrazinamide and probenecid tests

1 reference

12 December 2020

Origin and Extrarenal Elimination of Uric Acid in Man

1 reference

12 December 2020

Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort

1 reference

12 December 2020

Molecular identification of a renal urate anion exchanger that regulates blood urate levels

1 reference

12 December 2020

Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa, Japan

1 reference

12 December 2020

Stimulation of V1a receptor increases renal uric acid clearance via urate transporters: insight into pathogenesis of hypouricemia in SIADH

1 reference

12 December 2020

Role of the intestinal tract in the elimination of uric acid

1 reference

12 December 2020

Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial

1 reference

12 December 2020

Gout--is Lee's 2008 risk:benefit conclusion for benzbromarone hepatotoxicity still relevant today?

1 reference

12 December 2020

Ten years' experience with benzbromarone in the management of gout and hyperuricaemia

1 reference

12 December 2020

Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions

1 reference

12 December 2020

Uric Acid in Advanced Renal Failure

1 reference

12 December 2020

10.1007/S10157-016-1288-2

Identifiers

DOI

1 reference

7 September 2017

1 reference